Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.
Pulmonary arterial hypertension (PAH) is often difficult to diagnose and challenging to treat. Untreated, it is characterized by a progressive increase in pulmonary vascular resistance leading to right ventricular failure and death. The past decade has seen remarkable improvements in therapy, driven largely by the conduct of randomized controlled trials. Still, the selection of most appropriate therapy is complex, and requires familiarity with the disease process, evidence from treatment trials, complicated drug delivery systems, dosing regimens, side effects, and complications. This chapter will provide evidence-based treatment recommendations for physicians involved in the care of these complex patients. Due to the complexity of the diagnostic evaluation required, and the treatment options available, it is strongly recommended that consideration be given to referral of patients with PAH to a specialized center.
Badesch
David B
DB
University of Colorado Health Sciences Center, Denver, CO 80262, USA. David.Badesch@UCHSC.edu
Abman
Steve H
SH
Ahearn
Gregory S
GS
Barst
Robyn J
RJ
McCrory
Douglas C
DC
Simonneau
Gerald
G
McLaughlin
Vallerie V
VV
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D011651:Pulmonary Artery
D000959:Antihypertensive Agents